Umbilical Cord Mesenchymal Stem Cell

The application of mesenchymal stem cell (MSC) has been one of the most remarked topics in the related field. In January 2008, a well-known leader in developing and commercializing adult bone marrow stem cell therapies, Osiris Therapeutics, Inc., earned a 224-million-dollar (USD) contract with US Department of Defense regarding clinical study of MSC as countermeasure to nuclear or radiological events. Likewise, BIONET was approved for conducting an 84-million-dollar Leading Product Development project supported and supervised by Industrial Development Bureau, Ministry of Economic Affairs ROC, promoting MSC conceptional as well as clinical research in September 2006.

Research of MSC is mainly for regenerative medicines in the fields of treating Myocardial infarction, Parkinson's disease, et al. On the other hand, it has been reported that HSC/MSC co-infusion for hematopoietic regeneration may enhance engraftment. A number of domestic clinical studies in progress are investigating MSC: Veterans General Hospital and Tzuchi hospital have studied mesenchymal stem cells in the treatment of stroke; National Taiwan University hospital successfully utilized MSC in incubation of cartilaginous cells specialized for degenerative Arthritis, and an attempt to differentiate islet-like cells from MSC aiming at treatment for diabetes had been carried out.

BIONET had been and always kept seeking linkages actively with major medical research groups, biotechnology companies and academic institutes to accelerate progressive and realistic applications of stem cell. In particular, the regulatory issues connected with transplantation in clinical setting call for long-term partnership with medical centers and inspection agents, as BIONET has established collaborations with National Taiwan University Hospital, China Medical University Hospital, Chi Mei Hospital, Taipei Medical University (including Wan Fang Hospital), Buddhist Tzu Chi General Hospital, Tri-Service General Hospital, and Industrial Technology Research Institute (ITRI), and Academia Sinica.

‧訊聯政府相關單位補助計畫一覽表

執行日期	機關名稱	計畫名稱
2011年	中國醫藥大學附設醫院	與中國醫藥大學附設醫院合作，進行間質幹細胞MSC人體應用研究，4月發表最新成果，並獲得世界著明移植雜誌(Transplantation)青睞，稱讚這項研究讓全球醫學前進了一大步！
2010年	美國辛辛那提大學	與美國辛辛那提大學合作發表研究成果，証實臍帶間質幹細胞可輔助修復先天性眼角膜功能不全。
2010年	成功大學	與國立成功大學合作，進行臍帶間質幹細胞與牙齒幹細胞增生相關研究。
2010年	三軍總醫院	臍帶間質幹細胞與乳牙幹細胞輔助傷口修復的效益評估動物實驗—以裸鼠模式測試臍帶間質幹細胞與乳牙幹細胞輔助傷口修復的確效試驗
2010年	三軍總醫院	Establishment of a traceable mesenchymal stem cell model to track and target primary or metastatic human ovarian cancer cells 建立追蹤及標定人類癌細胞之可追蹤間質幹細胞模式
2010年	首度提供間質幹細胞給國外醫學中心	間質幹細胞人體醫療移植使用
2009年	亞東／台北科技大學	與亞東醫院暨台北科技大學合作爭取國科會產學計畫，以臍帶間質幹細胞(MSC)輔助軟骨再生的臨床前試驗。
2006年-2009年	合作臨床單位： 1.中國醫藥大學附設醫院 2.奇美醫院	主導性新商品研究計畫— 人類臍帶間質幹細胞及其衍生之應用
2006年-2008年	國立台灣大學	基因檢測標準化流程建立
2006年-2007年	李茂盛婦產科	評估以間質幹細胞為滋養層細胞共同培養人類胚幹細胞之效果
2006年~現在	北醫/萬芳醫院	以NOD/SCID實驗小鼠之動物實驗模式探討間葉性幹細胞/造血性幹細胞共同移植以治療血液性疾病之效果
2006年	長庚醫院	利用臍帶間質幹細胞修復角膜
2005年	慈濟醫院	間質幹細胞在中風及神經再生等應用之活體實驗
2005年	中央研究院	人類臍帶幹細胞之鑑定、分離、收集、培養、冷凍、解凍、運送及儲存
2005年	中央研究院	人類臍帶幹細胞分離儲存標準化流程建立
2004年-2006年	台北醫學大學	NOD/SCID小鼠移植之動物實驗模式建立
2004年-2006年	工研院	臍帶血多向性間葉幹細胞在移植及組織應用之技術開發
2003年-2004年	中國醫藥大學	由人類胎盤分離造血性與多向性幹細胞之最佳化流程
2003年-2004年	東華大學	臍帶血抗原抗體在臍帶血幹細胞之應用
2003年-2004年	東華大學	臍帶血幹細胞免疫分離法之開發研究
2003年	工研院	臍帶血多向性間葉幹細胞應用核心技術的建立
2003年	工研院	臍帶血多向性幹細胞的培養與增生技術開發計畫
2003年	國立台灣大學	Generation of Dendritic cell Precursors from Cord Blood Stem Cells
2002年-2004年	三軍總醫院	幹細胞在腦神經病變上之臨床治療應用
2002年-2003年	台大醫院	臍帶血多向性幹細胞誘導分化為骨細胞之應用

 

Our Publications

BIONET has been very uninhibited to exploit acknowledgment and visibility by participating international grouping and publishing research articles.

• By use of mesenchymal stem cells in hematopoietic stem cell transplantation, proliferation was found to be increased five times in an animal experiment. International Society for Cellular Therapy Annual Meeting. May 2006.
• Enhancing the Engraftment of Umbilical Cord Blood Hematopoietic Stem Cells by Co-infusion of Umbilical Cord-derived Mesenchymal Stem Cell in an NOD/SCID Mouse Model. AABB annual meeting, Seattle. October 2005.
• Isolation and identification of mesenchymal stem cells from placenta; Standardization of isolation, incubation and identification of mesenchymal stem cells for medical purpose. Asia bio-seminar hosted by Taiwan Association of Obstetrics and Gyneocology. September 2004.

The research team of BIONET has collaborated with one of the most representative research groups in the field of transplantation medicine, University of Minnesota, to develop a comprehensive quality assessment of cord blood processing protocol. Professor John Wagner, Director of Division of Pediatric Hematology-Oncology and Blood and Marrow Transplantation, University of Minnesota, has been invited onboard as chief consultant. Just recently Professor Wagner guided the research team of BIONET to conduct a two-year SBIR Phase II research project, Therapeutic Application of Multi-potent Mesenchymal Stem Cell of Cord Blood, approved and supported by Ministry of Economic Affairs, R.O.C.

 

BIONET has another equally essential focus on MSC application, as the research team under advisory of Professor Winston Kao, MED-Ophthalmology, University of Cincinnati, studies the regenerative potentials of MSC in ophthalmological field. Some preliminary results had been published in international ophthalmology seminar such as ARVO, discussing the research progress of treating corneal abnormality and reparability. Most of the projects lead by Dr. Winston Kao in US had been granted sponsorship by National Eye Institute, and accomplished a great number of successful animal studies for exploration on clinical utilization. The research team has formed a solid foundation for regenerative and reconstructive medicine for further studies. Some of the recent publications by Dr. Kao are listed below：

• Dependence of regulatory volume decrease on transient receptor potential vanilloid 4 (TRPV4) expression in human corneal epithelial cells.Cell Calcium. 2008 Oct;44(4):374-85. Epub 2008 Mar 19.
• Corneal wound healing in an osteopontin-deficient mouse. Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1367-75.
• Promiscuous recombination of LoxP alleles during gametogenesis in cornea Cre driver mice. Mol Vis. 2008 Mar 20;14:562-71.

And the following lists publications by Dr. Winston Kao in collaboration with BIONET:

• September, 2007 Pacific Ocular Regenerative Biology Conference, Laguna Beach, California (USA)
• April, 2008 ARVO Annual Meeting, at Fort Lauderdale, Florida
  Publication of results - “Corneal cells derived from MSC in an mice experiment”
• September 2008 18th International Congress of Eye Research, Beijing (China)
  Publication of results - “Evaluation of applicability of MSC applying in the treatment of corneal disorders in an animal experiment”

 

BIONET has been accredited by many international organizations of authentication regarding to the safety and quality of stem cell processing protocols. In particular, cells processed and crypreserved by BIONET laboratory had been recognized as applicable sources by University of Minnesota in 2005. Other international accreditations obtained during recent years include Europdonor (the initiatives of BMDW), Leiden University (Netherland), City of Hope National Medical Center (USA), and Fred Hutchinson Cancer Research Center.